Introduction
Gene expression, cellular differentiation, and survival are regulated by the opposing activities of histone acetyltransferases (HATs) and histone deacetylases (HDACs). HDAC inhibitors are a new treatment strategy in early clinical development against MM. inhibitors have synergistic cytotoxicity against MM, 4, 5, 7 as have tyrosine kinase inhibitors. [6] [7] [8] [9] [10] Phase I and II clinical trials of hydroxamic acid-derived HDAC inhibitors suberoylanilide hydroxamic acid (SAHA) and LBH589 for the treatment of MM are now underway in the United
States.
The 26S proteasome is a large ubiquitous protein complex with multiple non-lysosomal proteolytic functions essential in regulating diverse cellular functions including: cell cycle, apoptosis and resistance to drug-induced cell death; antigen presentation by MHC class I molecules; degradation of intracellular proteins regulating cell adhesion, transcription, and angiogenesis;
For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From rapid elimination of abnormally folded or oxidized proteins. [11] [12] [13] [14] [15] [16] [17] [18] [19] Misfolded proteins are non functional and prone to forming aggregates that can interfere with normal cellular function. 20 The mammalian unfolded protein response (UPR) protects the cell against the stress of misfolded proteins. 21, 22 Importantly, the increased protein turnover in plasma cells, and in particular MM cells, suggests the importance of the UPR in conferring sensitivity of MM cells to proteasome inhibition.
When the production of unfolded and misfolded ubiquitinated proteins exceeds the capacity of cellular proteasomes to degrade them, they accumulate in aggresomes. Aggresomes are microtubule (MT)-based inclusion bodies formed by the retrograde transport of aggregated protein on MTs, and represent a general cellular response to the presence of misfolded proteins. 23, 24 Aggresomes form initially as small protein aggregates that coalesce at dispersed sites throughout the periphery of the cytoplasm. They then travel on MTs to the MT organizing center (MTOC) region, where they remain as distinct but closely apposed stable particulate structures entangled with collapsed intermediate filaments. 23, 25 Tubulin acetylation plays an important role in the differentiation of MT structure and function. Acetylation of α-tubulin is a posttranslational modification consisting of the addition of an acetyl group to lysine 40, which is reversed by tubulin deacetylase (TDAC, or HDAC6).
TDAC is an enzyme with deacetylase and ubiquitin binding activity, and both activities are required for TDAC to regulate aggresome formation. 26 TDAC binds both polyubiquitinated misfolded proteins and dynein, recruiting misfolded protein to dynein motors for transport to aggresomes along MTs. Aggresome formation is paralleled by the redistribution of the intermediate filament protein vimentin and the recruitment of proteasomes and chaperonins, a process dependent specifically on TDAC activity. 26 There are 3 main classes of HDACs. TDAC belongs to class II HDACs, which all show homology to yeast Hda1. TDAC is unique among the class II members in that it has two catalytically active HDAC domains and also a C-terminal zinc finger domain that binds ubiquitin. 27 The second catalytic domain in TDAC confers resistance to the HDAC inhibitors trapoxin B and sodium butyrate. 28, 29 TDAC is also resistant to HDAC inhibitors depsipeptide FR9012208 and the hybrid compound cyclic hydroxamic acid-containing peptide CHAP1, 30 whereas trichostatin A and SAHA inhibit TDAC to a similar extent as other HDACs. 31, 32 In this study, we evaluated the activity of the novel hydroxamic acid derived HDAC inhibitor LBH589 against MM cells; delineated LBH589-induced apoptotic signaling; determined whether synergistic cytotoxicity is induced with bortezomib; as well as defined effects of LBH589, alone or
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Materials and methods

TDAC/HDAC inhibitor; proteasome inhibitor
LBH589 (Novartis Pharmaceuticals Inc., East Hanover, NJ) and bortezomib (Millennium, Cambridge, MA) were dissolved in de-iodinized water and stored at -20°C, thawed and diluted in media for cell culture experiments.
MM-derived cell lines and patient cells
Dexamethasone (Dex)-sensitive (MM.1S) and Dex-resistant (MM.1R) human MM cell lines, as well as RPMI8226 cells resistant to Doxorubicin (Dox40), Mitoxantrone (MR20), and Melphalan (LR5), were cultured in RPMI1640 media (Cellgro, Mediatech, VA) with 10% fetal bovine serum, 2 mmol/L L-glutamine (GIBCO, Grand Island, NY), 100 U/mL penicillin, and 100 mg/mL streptomycin (GIBCO). Drug-resistant cell lines were cultured with doxorubicin, mitoxantrone, melphalan, or Dex to confirm their lack of drug sensitivity. MM patient cells were obtained from bone marrow samples taken with permission for research purposes. Bone marrow mononuclear cells were separated using Ficoll-Hipaque density sedimentation, and plasma cells were purified 
Growth Inhibition Assay
The inhibitory effect of LBH589 on MM cell growth was assessed by measuring 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium, inner salt (MTS) (Promega, Madison, WI) dye absorbance of cells. Cells in 200 µL media plus drug were pulsed with 40 µL of 5 mg/ml MTS to each well for the last 4 h of 48 h cultures. Absorbance was measured at 490 nm using a spectrophotometer (Molecular Devices Corp., Sunnyvale, CA).
Immunoblotting
MM.1S cells were cultured with up to 100 nM LBH589; harvested; washed; and lysed using lysis buffer: RIPA buffer, 2 mmol/L Na3VO4, 5 mmol/L NaF, 1 mmol/L phenylmethyl sulfonyl fluoride (PMSF), 5 mg/mL leupeptin, and 5 mg/mL aprotinin. Cell lysates were subjected to SDS-PAGE, Dex-sensitive MM.lS cells express high levels of the glucocorticoid receptor (GR), whereas Dexresistant MM.IR cells express low to undetectable levels of a functional GR. 34 In contrast, induced cleavage of caspases-8, -9, and -3 as well as PARP. The promoter for p21 transcription is regulated by histone acetylation status, 50 and up-regulation of p21 has been widely reported with HDAC inhibitors. 51, 52 As we previously reported with NVP-LAQ824, 5 p21 up-regulation was triggered at low nanomolar concentrations of LBH589. In contrast, the oncogene c-myc was down-regulated. (Fig 5B, left panel) ; 13% of cells were viable with segmented hyperacetylated α-tubulin (Fig 5B, center panel) ; 40% of cells were apoptotic with diffuse α-tubulin. No aggresomes were observed when cells were treated with low-dose LBH589 alone. Cells treated with bortezomib 16 nM displayed normal appearance in 40%; 8% displayed aggresome formation associated with normal reticulated acetylated α-tubulin (Fig 5C, left panel) ; 28% were apoptotic with diffuse α-tubulin; 17% were apoptotic with aggresome formation associated with reticulated acetylated α-tubulin, although reticulated acetylated α-tubulin in association with apoptosis was more segmented with a tendency to polarize within the cell ( The current experiments demonstrate striking synergistic cytotoxic activity induced by LBH589 in combination with bortezomib, which is partially caspase-dependent. In general, caspasemediated apoptosis is triggered via initiator caspases (caspases-8 and -9) and downstream effector caspases (caspases-3, -6 and -7), and occurs when the activity of pro-apoptotic molecules such as reactive oxygen species (ROS) overcome anti-apoptotic mechanisms, such as activation of nuclear factor κ-B. Synergy has been observed between bortezomib and the anthracycline antibiotic doxorubicin via inhibition of DNA repair enzymes, 54 and between bortezomib and the topoisomerase-1 inhibitor SN38 via inhibition of nuclear factor κ-B.
Results
LBH589 inhibits growth viability of MM cell lines resistant to conventional chemotherapy
53,55
Synergistic apoptosis induced by bortezomib in combination with SAHA and sodium butyrate is mediated via mitochondrial dysfunction and ROS-dependent mechanisms, and downstream events include nuclear factor κ-B inactivation, c-Jun NH terminal kinase activation, p53 induction, caspase activation, PARP cleavage, and caspase-dependent cleavage of p21, p27, bcl-2, mcl-1, X-linked inhibitor of apoptosis, and down-regulation of cyclin D1. 6, 56 Therefore, a number of potential molecular mechanisms may contribute to mediating the synergy between bortezomib and LBH589. In the current studies, we investigated a potential novel interaction between upstream apoptotic triggers specific to both bortezomib and LBH589. Given the roles of proteasome inhibition and TDAC in the misfolded protein response and aggresome formation, we
For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From explored the effects of bortezomib and LBH589 on α-tubulin cytoarchitecture and aggresome formation. Untreated interphase cells were observed to form a branching cytoskeletal network of acetyl-α-tubulin extending to the cell periphery. Exposure to low concentrations of LBH589 induced α-tubulin hyperacetylation that was either diffuse or segmented, and mostly associated with normal nuclei. Apoptotic nuclei were associated with non-specific cytoplasmic α-tubulin architecture, and visible aggresomes were not induced at low concentrations of LBH589.
Exposure to bortezomib induced aggresome formation with preservation of the cytoskeletal architecture in cells with normal nuclei, whereas focal discrete aggresomes were associated with apoptotic nuclei. After exposure to LBH589 in combination with bortezomib, the effects of each drug alone were significantly augmented. Aggresomes and hyperacetylated α-tubulin aggregates were significantly increased in apoptotic cells, with a marked overall increase in apoptotic nuclei.
Although TDAC inhibition would be expected to inhibit aggresome formation, 26 the addition of bortezomib induced a slight increase in aggresome numbers, but these aggresomes were smaller, and the cells were apoptotic. The most striking feature was the development of large bundles of hyperacetylated α-tubulin, which were abnormally displaced from their usual extended cytoplasmic distribution. These changes have been previously described with the intermediate filament vimentin in cells over-expressing the inefficiently folded integral membrane cystic fibrosis transmembrane conductance regulator (CFTR) which were exposed to the MT inhibitor nocodozole, and suggest increased demand on the aggresome pathway coupled with inhibition of MT cytodynamics. These findings are consistent with the TDAC inhibitory properties of LBH589 in combination with aggresome induction by bortezomib.
23,24
The aggresome pathway prevents a widespread intracellular accumulation of misfolded proteins that escape the other protective processes within the cell, in particular proteasome inhibition.
Prominent aggresomes or inclusion bodies are not normally evident in unstressed cells. The life spans of cells containing aggresomes induced by over-expression of misfolded proteins are similar to normal cells. 25 However, if the pathway is overwhelmed, the continuing accumulation of protein aggregates is detrimental. 24 Cells deficient in TDAC cannot form aggresomes properly, fail to clear misfolded protein aggregates from the cytoplasm, and are hypersensitive to the accumulation of misfolded proteins. In TDAC knockdown cells that do form visible aggresomes in response to proteasome inhibition, aggresome size is significantly smaller than in normal cells. 26 TDAC is therefore very important in the cellular management of misfolded protein induced stress.
Like LBH589, the more selective TDAC inhibitor tubacin is also synergistic with bortezomib against MM cells. 57 One notable difference between tubacin and LBH589 is that tubacin did not induce p21 up-regulation, which is an almost universal feature of HDAC inhibitors. 51 This difference is consistent with regulation of the promoter for p21 transcription by histone acetylation 50 LBH589 is cytotoxic in low nanomolar concentrations (IC50 <100 nM) for all myeloma cells tested, whereas the cytotoxic IC50 for tubacin is over 5 micromoles for most cells tested.
However, the different potencies also apply to TDAC inhibitory activity, and may not necessarily and α-tubulin hyperacetylation are induced by LBH589 simultaneously because both are mediated by TDAC inhibition. 60 Similarly, bortezomib inhibits the unfolded protein response in myeloma which may contribute to aggresome formation. 21 It will be important to determine the contribution of each mechanism to the synergistic interactions between bortezomib and LBH589.
Ongoing studies are also delineating the role of MT-dependent retrograde transport of aggregated protein during MM cell apoptosis. Resolution of these issues may identify key targets involved in cellular trafficking pathways in MM, and reveal insights into the selective activity of bortezomib against MM cells.
In conclusion, LBH589 represents a novel hydroxamic acid-derived HDAC inhibitor with activity against MM in nanomolar concentrations, which should be readily achievable in patients. Strong synergy against MM cells was observed with bortezomib, which was associated with marked Patterns of α-tubulin acetylation and aggresome formation were classified as described in materials and methods. Cell counts were performed on at least 150 cells in each treatment group.
Morphological patterns defined by acetyated α-tubulin were further classified based upon nuclear appearance to be either normal or apoptotic. A representative set of counts from 3 separate experiments is shown in Figure 6 . 
